Ayman Saker
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ayman Saker has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Andrea De La Hoz
Department of Lawson Research—Medicine, London Health Sciences Centre, London, ON N6A 5W, Canada
1 shared publication - Jejelola Ladele
Department of Pediatrics, Division of Neonatal Perinatal Medicine, Western University, London, ON N6A 3K7, Canada
1 shared publication - Michael R. Miller
Department of Pediatrics, Western University, London, ON, Canada
1 shared publication - Renjini Lalitha
University of Western Ontario
1 shared publication - Soume Bhattacharya
Paediatrics, Western University, London, Ontario, CANADA
1 shared publication - Talal Altamimi
Department of Pediatrics, Division of Neonatal Perinatal Medicine, Western University, London, ON N6A 3K7, Canada
1 shared publication
Latest Publications
- Open Access
- 17 October 2023
- Published by MDPI AG in Applied Sciences
- Vol. 13 (20) , 11380
Improved Cardiac Performance with Dexamethasone Therapy in Premature Neonates: Novel Insights Using Serial Echocardiographic Assessments
(1) Background: dexamethasone is used for the prevention and treatment of chronic lung disease (CLD) in premature neonates, and its impact on cardiac performance and pulmonary vascular resistance has not been well studied. (2) Methods: eligible neonates of p = 0.025), tricuspid annular plane systolic excursion (TAPSE 0.65 cm vs. 0.70 cm, p = 0.013), and RV S’ (7.18 vs. 8.56, p = 0.05). The left ventricular (LV) ejection fraction was similar but with a significant increase in the LV S’ (4.77 vs. 6.01, p = 0.006). A longitudinal analysis at three time points showed a significant increase in RV FAC (0.02 units 95% CI (0.00–0.04), p = 0.037), TAPSE (0.09 units 95% CI (0.06–0.13), p < 0.001), RV S’ (0.97 units (95% CI = 0.11–1.84), p = 0.028), a reduction in the eccentricity index (0.07 units 95% CI (−0.14–−0.01), p = 0.030), and an increase in the LV S’ (0.56 units (95% CI = 0.18–0.94)). (4) Conclusion: The use of postnatal dexamethasone for the prevention/treatment of CLD in premature neonates resulted in an expected improvement in respiratory status along with a significant improvement in the echocardiographic measures of biventricular heart performance.
- 17 October 2023
- Published by MDPI AG in Applied Sciences
- Vol. 13 (20) , 11380
Open AccessImproved Cardiac Performance with Dexamethasone Therapy in Premature Neonates: Novel Insights Using Serial Echocardiographic Assessments
(1) Background: dexamethasone is used for the prevention and treatment of chronic lung disease (CLD) in premature neonates, and its impact on cardiac performance and pulmonary vascular resistance has not been well studied. (2) Methods: eligible neonates of p = 0.025), tricuspid annular plane systolic excursion (TAPSE 0.65 cm vs. 0.70 cm, p = 0.013), and RV S’ (7.18 vs. 8.56, p = 0.05). The left ventricular (LV) ejection fraction was similar but with a significant increase in the LV S’ (4.77 vs. 6.01, p = 0.006). A longitudinal analysis at three time points showed a significant increase in RV FAC (0.02 units 95% CI (0.00–0.04), p = 0.037), TAPSE (0.09 units 95% CI (0.06–0.13), p < 0.001), RV S’ (0.97 units (95% CI = 0.11–1.84), p = 0.028), a reduction in the eccentricity index (0.07 units 95% CI (−0.14–−0.01), p = 0.030), and an increase in the LV S’ (0.56 units (95% CI = 0.18–0.94)). (4) Conclusion: The use of postnatal dexamethasone for the prevention/treatment of CLD in premature neonates resulted in an expected improvement in respiratory status along with a significant improvement in the echocardiographic measures of biventricular heart performance.